Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 1.00 |
| ▸ | PDE4A | P27815 | 13/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 13/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 13/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
| ▸ | PDE1A | P54750 | 1/20 | 0.70 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.70 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5583187 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL30571023 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL5583471 | 0.88 | PDE4A (0.78) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL595898 | 0.88 | PDE4A (0.78) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2532096 | 0.86 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL2529312 | 0.86 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL2529551 | 0.86 | PDE4B (0.76) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL2527365 | 0.86 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL2531139 | 0.86 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL7995576 | 0.86 | PDE4B (0.76) | PDE4BPDE4APDE4CPDE4DCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340530-A1 | Methods of Protecting RNA | PFIZER INC. (US) | 2023-10-26 | — | — | US | claimed |
| EP-4204012-A1 | METHODS OF PROTECTING RNA | Pfizer Inc. (US) | 2023-07-05 | — | — | EP | claimed |
| US-20240358728-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240206470-A1 | VOLATILE APPLICATIONS AGAINST PATHOGENS | AGROFRESH INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230340530-A1 | Methods of Protecting RNA | PFIZER INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230340530-A1 | Methods of Protecting RNA | PFIZER INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-11771089-B2 | Large-scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness | AGROFRESH INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766043-B2 | Vaporized administration of pesticides | AGROFRESH INC. (US) | 2023-09-26 | — | — | US | disclosed |
| EP-4204012-A1 | METHODS OF PROTECTING RNA | Pfizer Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230008130-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3708568-B1 | COMPOUND CAPABLE OF INHIBITING PHOSPHODIESTERASE 4, PREPARATION METHOD, AND MEDICAL USE THEREOF | HEFEI INDUSTRIAL PHARMACEUTICAL INST CO LTD (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1212327-B8 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008130-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | PDE4B 948/4885PDE4A 1385/4885PDE4C 2189/4885 |
| US-20240206470-A1 | VOLATILE APPLICATIONS AGAINST PATHOGENS | OXA1L, VAPB, TIAL1 | PDE4B 2903/4885PDE4A 3573/4885PDE4C 3602/4885 |
| US-20240358728-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | PDE4B 948/4885PDE4A 1385/4885PDE4C 2189/4885 |
| US-11766043-B2 | Vaporized administration of pesticides | GPX4, CAT, PRDX2 | PDE4B 1459/4885PDE4A 1522/4885PDE4C 1124/4885 |
| US-11771089-B2 | Large-scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness | TAS2R10, FOSB, TMBIM6 | PDE4B 1464/4885PDE4A 2280/4885PDE4C 2392/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | PDE4B 806/4885PDE4A 686/4885PDE4C 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.